EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Lysophosphatidic acid metabolism and signaling in heart disease

Anu Jose, Jeffy J Fernando, Petra C Kienesberger iD

Canadian Journal of Physiology and Pharmacology · 01.12.2024 · 102 (12) · 685-696

DOI: 10.1139/cjpp-2024-0077 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Canadian Journal of Physiology and Pharmacology, erschienen am 01.12.2024. Verfasst von Anu Jose und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Dalhousie University, Dalhousie Medicine New Brunswick, Saint John, NB, Canada. Hauptthemen laut MEDLINE: Lysophospholipids, Signal Transduction, Heart Diseases, Receptors, Lysophosphatidic Acid. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute of Circulatory and Respiratory Health, Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lysophosphatidic acid (LPA) is a bioactive lipid that is mainly produced by the secreted lysophospholipase D, autotaxin (ATX), and signals through at least six G protein-coupled receptors (LPA1–6). Extracellular LPA is degraded through lipid phosphate phosphatases (LPP1, LPP2, and LPP3) at the plasmamembrane, terminating LPA receptor signaling. The ATX–LPA–LPP3 pathway is critically involved in a wide range of physiological processes, including cell survival, migration, proliferation, angiogenesis, and organismal development. Similarly, dysregulation of this pathway has been linked to many pathological processes, including cardiovascular disease. This review summarizes and interprets current literature examining the regulation and role of the ATX–LPA–LPP3 axis in heart disease. Specifically, the contribution of altered LPA metabolism via ATX and LPP3 and resulting changes to LPA receptor signaling in obesity cardiomyopathy, cardiac mitochondrial dysfunction, myocardial infarction/ischemia-reperfusion injury, hypertrophic cardiomyopathy, and aortic valve stenosis is discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LysophospholipidsSignal TransductionHeart DiseasesReceptors, Lysophosphatidic AcidPhosphoric Diester HydrolasesHumansAnimalsPhosphatidate PhosphataseLysophospholipase D

Stichwörter der Autor:innen

autotaxincardiomyopathyheart diseaselipid phosphate phosphataselysophosphatidic acid

Substanzen

LysophospholipidsReceptors, Lysophosphatidic AcidPhosphoric Diester HydrolasesPhosphatidate PhosphataseLysophospholipase Dlysophosphatidic acid

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Dalhousie University, Dalhousie Medicine New Brunswick, Saint John, NB, Canada.

ORCID-Profile: Petra C Kienesberger

Förderung

  • Institute of Circulatory and Respiratory Health
  • Natural Sciences and Engineering Research Council of Canada

Zitieren

APA

Jose, A., Fernando, J. J., & Kienesberger, P. C. (2024). Lysophosphatidic acid metabolism and signaling in heart disease. Canadian Journal of Physiology and Pharmacology, 102(12), 685-696. https://doi.org/10.1139/cjpp-2024-0077

Vancouver

Jose A, Fernando JJ, Kienesberger PC. Lysophosphatidic acid metabolism and signaling in heart disease. Canadian Journal of Physiology and Pharmacology. 2024;102(12):685-696. doi:10.1139/cjpp-2024-0077

BibTeX
@article{Jose2024,
  author = {Jose, Anu and Fernando, Jeffy J and Kienesberger, Petra C},
  title = {Lysophosphatidic acid metabolism and signaling in heart disease},
  journal = {Canadian Journal of Physiology and Pharmacology},
  year = {2024},
  volume = {102},
  number = {12},
  pages = {685--696},
  doi = {10.1139/cjpp-2024-0077}
}
Kostenlos starten →